May 13 2010
AlphaRx, Inc. (OTCBB: ALRX), has been advised by Cypress Biosciences ("Cypress"), its development partner for Indaflex, that Cypress is not funding development of Indaflex. Notwithstanding to the termination of all Indaflex activity in the U.S.A., AlphaRx continues to develop Indaflex for the Chinese market. AlphaRx is working diligently with its regulatory consultants in the preparation for submission of a CTA (clinical Trial Application) with the China SFDA in order to begin human trials in China. These preparations are proceeding on schedule.